Until now, the immune sensor TLR8 has remained in the shadows of science. A research team has now discovered how this sensor plays an important role in defending human cells against intruders. The ...

Use of quantum dots-based immunofluorescence nanotechnology for quantitative HER2 and ER detection in breast cancer tissue array to identify correlations in HER2-overexpressed and ER-positive breast ...

Shanghai Visonpharma Co. Ltd. has identified pyridine [4,3-d]pyrimidine compounds acting as Toll-Like receptor 7 (TLR7) and TLR8 agonists reported to be useful for the treatment of cancer and viral ...

Researchers have discovered a new mechanism by which live vaccines induce immunity. Molecules produced exclusively by live microorganisms are recognized by specialized receptors of the immune system, ...

Immune cells in our bodies use toll-like receptors (TLRs) to recognize bits and pieces of invading pathogens. For example, one type of TLR, TLR8, sits in the membranes of cellular compartments called ...

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (“Silverback”) (“the Company”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop ...

Innovent Biologics (Suzhou) Co. Ltd. has described antibody-stimulating antibody conjugates (ISACs) comprising antibody targeting folate receptor α (FOLR1; FR-α) or tumor-associated calcium signal ...

Celgene secured an option to acquire VentiRx Pharmaceuticals as part of an exclusive worldwide collaboration centred on development of the latter’s clinical-stage anticancer TLR8 agonist VTX-2337.

Seattle, WA– October 3, 2012 –VentiRx Pharmaceuticals, Inc., a privately held biopharmaceutical company dedicated to the development of novel Toll-like receptor 8 (TLR8) agonists and antagonists today ...

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop ...